| 2.335 -0.065 (-2.71%) | 08-31 14:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.47 |
| Resists | First : | 2.54 | Second : | 2.97 |
| Pivot price | 2.37  |
|||
| Supports | First : | 2.11 | Second : | 1.85 |
| MAs | MA(5) : | 2.44  |
MA(20) : | 2.29 |
| MA(100) : | 2.5 |
MA(250) : | 3.98 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.9 |
D(3) : | 80 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 6.88 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMPX ] has closed above bottom band by 38.5%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 73 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.53 | 2.53 - 2.54 |
| Low: | 2.37 - 2.38 | 2.38 - 2.4 |
| Close: | 2.38 - 2.4 | 2.4 - 2.42 |
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Fri, 28 Aug 2026
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 26 Aug 2026
CMPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Thu, 06 Aug 2026
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains - Stock Titan
Thu, 06 Aug 2026
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 15 Jul 2026
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity - Seeking Alpha
Fri, 03 Jul 2026
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 88.6 (%) |
| Shares Short | 39,870 (K) |
| Shares Short P.Month | 37,140 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.1 % |
| Return on Equity (ttm) | -56.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -5.99 |
| PEG Ratio | 0 |
| Price to Book value | 2.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|